Destiny Pharma Seeks Partner For Lead Asset XF-73
Destiny CEO Believes Superbug Gel Will Draw Backing
Executive Summary
Antimicrobial specialist Destiny Pharma aims to enlist a pharma partner later this year to help advance and launch its lead asset for preventing post-surgical infections.
You may also be interested in...
AMR Crisis Experts See Hopeful Signs For 2020
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.